featured
Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients With Castration-Resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet Oncol 2019 Feb 06;[EPub Ahead of Print], M Smith, C Parker, F Saad, K Miller, B Tombal, QS Ng, M Boegemann, V Matveev, JM Piulats, LE Zucca, O Karyakin, G Kimura, N Matsubara, WC Nahas, F Nolè, E Rosenbaum, A Heidenreich, Y Kakehi, A Zhang, H Krissel, M Teufel, J Shen, V Wagner, C HiganoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.